Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
ICD-O-3 Morphology
9871/3: Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16) (p13.1;q22), CBFB/MYH11
Effective 2001 and later
for cases diagnosed 2001 and later
Primary Site(s)
Primary site must be bone marrow (C421)

Code grade specified by pathologist. If no grade specified, code 9
Module Rule
See abstractor notes
Alternate Names
Acute myeloid leukemia, CBF-beta/MYH11
Acute myeloid leukemia, inv(16)(p13;q22)
Acute myeloid leukemia, t(16;16)(p13;q11)
Acute myelomonocytic leukemia with abnormal eosinophils
Acute myeloid leukemia that usually shows monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the marrow. Myeloid sarcomas may be present at initial diagnosis or relapse
Abstractor Notes
The acute myeloid leukemias with related precursor neoplasms are characterized by recurrent genetic abnormalities of prognostic significance. This specific disease is an acute myeloid leukemia with abnormal marrow eosinophils.

In addition to the usual morphological features of acute myelomonocytic leukemia, the BM shows a variable number of eosinophils (usually increased but sometimes less than five percent). The most striking abnormalities include the immature eosinophilic granules, usually present at later stages of disease.

If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Genetics Data
CD4+ (monocytic)
CD11b+ (monocytic)
CD11c+ (monocytic)
CD13+ (granulocytic)
CD14+ (monocytic)
CD15+ (granulocytic)
CD33+ (granulocytic)
CD36+ (monocytic)
CD64+ (monocytic)
CD65+ (granulocytic)
Lysozyme+ (monocytic)
MPO+ (granulocytic)
Transformations to
Corresponding ICD-9 Codes
205.0 Acute myeloid leukemia
Corresponding ICD-10 Codes
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C92.0 Acute myeloblastic leukemia (effective October 01, 2015)
Signs and Symptoms
Easy bruising or bleeding
Shortness of breath
Weight loss or loss of appetite
Progression and Transformation
Longer complete remissions when treated with high dose cytarabine in the consolidation phase
Older patients and those with KIT mutations have higher risk of relapse and worse survival
Epidemiology and Mortality
Age: predominantly younger patients
Incidence: 5-8% of all cases of AML
Survival: longer complete remissions possible when treated with high dose cytarabine in the consolidation phase